Platin-based chemotherapy does not improve survival in patients with non-metastatic resected typical carcinoid tumors

Creative Commons License

ŞAHİN A. B., MELEK H., OCAK B., OYUCU ORHAN S., ERKAN B., CANER B., ...Daha Fazla

MOLECULAR AND CLINICAL ONCOLOGY, cilt.17, sa.4, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3892/mco.2022.2579
  • Dergi Adı: MOLECULAR AND CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE
  • Anahtar Kelimeler: lung carcinoid, typical carcinoid, chemotherapy, stage, survival, SOCIETY EXPERT CONSENSUS, ADJUVANT CHEMOTHERAPY, NEUROENDOCRINE TUMORS, LUNG-CANCER, GUIDELINES, MANAGEMENT, DIAGNOSIS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Chemotherapy is controversial in non-metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin-based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non-metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease-free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin-based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log-rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin-based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non-metastatic TC. Although resection has satisfying long-term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.